GSK to buy in APIs rather than keep Indian plant running

GlaxoSmithKline ($GSK) will turn to outsourcing to replace APIs made at an Indian plant on its way to closure. Rather than sink more capital into improving the Thane, India, plant, the company will contract for those ingredients, which are "available at competitive prices from third-party manufacturers in India," a spokeswoman said. Some 330 employees are taking "voluntary retirement." Report

Like what you're reading?
Click here to get more news like this delivered to your inbox>>

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.